INTRODUCTION
Ischemic brain injury involves a complex pathophysiological cascade that comprises many distinct pathological stressors, including hypoxia, oxidative stress, inflammation, and glutamate excitotoxicity (Dirnagl et al., 1999; Lo et al., 2003) . A number of molecules and compounds conferring resistance to these stresses have been identified; however, they have failed to be protective in clinical trials despite promising preclinical data (Ikonomidou and Turski, 2002; Lee et al., 1999; Lo et al., 2003) . The accumulation of intracellular calcium (Ca 2+ ) in neurons after ischemia is a major determinant of ischemic cell death (Lo et al., 2003) . Several recent studies have suggested that some of these limitations may be circumvented by targeting excitotoxic signaling pathways downstream of NMDA receptors (NMDARs) (Hardingham et al., 1999 (Hardingham et al., , 2002 Taghibiglou et al., 2009 ). The activation of NMDARs has been linked to the modulation of a number of transcriptional factors, with either pro-survival or pro-death activity, suggesting that the alteration of transcription factor activity may crucially contribute to excitotoxic neuronal injuries (Taghibiglou et al., 2009 ). In particular, we and others have demonstrated that the transcription factor cAMP responsive element (CRE)-binding protein (CREB) protected the brain from ischemia mainly via its downstream neuroprotective genes (Hardingham et al., 2002; Mabuchi et al., 2001; Peng et al., 2006) . NMDAR subtypes and localization have attracted much attention because synaptic and extrasynaptic NMDARs have been shown to exert distinct roles in excitotoxicity (Sattler et al., 2000) . In particular, synaptic NMDARs, predominantly NR2A receptor subtypes, and extrasynaptic NMDARs, mainly NR2B subtypes, have opposite effects on CREB function, gene regulation, and neuronal survival (Hardingham et al., 2002; Peng et al., 2006; Liu et al., 2007) . Moreover, CREB also plays a pivotal role in an ischemic tolerance phenomenon in which brief sublethal ischemic insults (or preconditioning) protect neurons against a subsequent severe ischemic injury (Kitagawa, 2007; Mabuchi et al., 2001) . CREB contributes to neuroprotection by inducing its target genes, such as brain-derived neurotrophic factor (BDNF), peroxisome proliferator-activated receptor gamma coactivator 1 alpha (Ppargc-1a: its product is known as PGC-1a), and B cell lymphoma 2 (Bcl-2) (Mabuchi et al., 2001; St-Pierre et al., 2006) . In neurons, CREB-dependent gene expression has been implicated in complex and diverse processes, including development and plasticity (Lonze and Ginty, 2002) . The activity of CREB is regulated by phosphorylation, and Ser133 was found to be its crucial phosphorylation site (Gonzalez and Montminy, 1989) . Protein kinase A (PKA) is activated in the cAMP-signaling cascade and phosphorylates CREB at Ser133, enhancing its binding to the coactivators CREB-binding protein (CBP) and p300 (Vo and Goodman, 2001) . CBP/p300 then promote histone-chromatin remodeling through their intrinsic histone acetyltransferase activity and recruit basal transcription machinery to CRE-containing promoters (Goodman and Smolik, 2000) . Ca 2+ /calmodulin-dependent protein kinase I/IV (CaMK I/IV) are important isoforms of CaMKs in neurons and play pivotal roles in cell survival. Indeed, CaMK IV is recognized as a key mediator of CREB-dependent cell survival in neurons because treatment with a CaMK inhibitor renders neurons vulnerable to ischemia concomitant with the loss of CREB phosphorylation at Ser133 (Mabuchi et al., 2001 ). However, phosphorylation of CREB at Ser133 alone is not sufficient to fully activate the expression of target genes in peripheral tissues and the central nervous system (CNS), suggesting that the initiation of transcription of CREB target genes is controlled by CREB phosphorylation at Ser133 and possibly by other mechanisms Kornhauser et al., 2002) . The discovery of a family of coactivators named transducer of regulated CREB activity (TORC, also known as CREB regulated transcriptional coactivator [CRTC] , with three isoforms TORC1-3) provided new insights on CREB activation (Conkright et al., 2003; Iourgenko et al., 2003) . Under nonstimulated conditions, TORC is phosphorylated and sequestered in the cytoplasm. Once dephosphorylated in response to Ca 2+ and cAMP signals, it translocates to the nucleus (Bittinger et al., 2004; Screaton et al., 2004) . In contrast to CBP/p300, TORC activates transcription by targeting the basic leucine-zipper (bZIP) domain of CREB in a phospho-Ser133-independent manner. TORC1 is abundantly expressed in the brain and plays an important role in hippocampal long-term potentiation at its late phase (Ková cs et al., 2007; Zhou et al., 2006) . TORC2 is the most abundant TORC isoform in the liver and has been found to be involved in the gene expression of gluconeogenic programs and in the survival of pancreatic b cells (Koo et al., 2005) . Salt-inducible kinase (SIK) was identified as an enzyme induced in the adrenal glands of rats fed with a high-salt diet (Wang et al., 1999) . SIK isoforms (SIK1-3) belong to a family of AMP-activated protein kinases (AMPKs). SIK1 expression is induced by depolarization in the hippocampus and plays a role in the development of cortical neurons through the regulation of TORC1 (Feldman et al., 2000; Li et al., 2009 ). However, it remains to be clarified whether the intracellular signaling of SIK-TORC is crucial for CREB-dependent neuronal survival, and if so, what acts as the upstream signaling cascade.
In the present study we found high expression levels of SIK2 in neurons. The levels of SIK2 protein were lowered after ischemic injury and were accompanied by the dephosphorylation of TORC1. CaMK I/IV play an important role in the regulation of the SIK2 degradation by phosphorylating SIK2 at Thr484. To assess the importance of SIK2 during ischemic injury in vivo, we generated SIK2 knockout (sik2 À/À ) mice and found that they showed resistance to ischemic neuronal injury.
RESULTS

CREB Phosphorylation at Ser133 and CRE-Mediated
Transcription during and after Oxygen-Glucose Deprivation in Cultured Cortical Neurons One hour after OGD in the primary cortical cultures, CREB was phosphorylated, and the level of phosphorylation reached a maximum at 3-6 hr after reoxygenation, then declined to basal levels after 12 hr post-reoxygenation ( Figure 1A and S1A available online). To measure CRE activity, neurons were infected with an adenovirus as a CRE reporter. We found a significant enhancement of CRE activity after 3-12 hr post-reoxygenation ( Figure 1B ). During OGD and early (1 hr) after reoxygenation, CREB phosphorylation was not followed by an increase in CRE activity, but late (12 hr) after reoxygenation, CRE activity remained high, regardless of the basal level of CREB phosphorylation. The results of a reporter assay using Gal4-fusion Ser133-disrupted CREB suggested the presence of the Ser133-independent activation of CREB following OGD ( Figure S1B ). To examine Ser133-independent regulation in cortical neurons, we performed CRE-reporter assays in the presence of cAMP agonists and a kinase inhibitor. Staurosporine at low dose (10 nM), a nonspecific kinase inhibitor, decreased the level of phospho-Ser133, but it induced the activity of a CRE reporter to comparable levels as the phospho-Ser133-inducer db-cAMP or forskolin ( Figure S1C ), suggesting the involvement of another type of CREB coactivator, TORC.
It has been shown that CREB activity is blocked by the inhibition of calcineurin. Indeed, we found this to be true in neurons after OGD because the calcineurin inhibitor cyclosporine A (CsA) and FK 506 suppressed CRE activity ( Figure 1C ), despite the upregulation of CREB phosphorylation by FK 506 (Figure 1C) . The mechanism by which calcineurin activates CREB could be the dephosphorylation-dependent nuclear entry of CREB-coactivator TORCs. To examine the activity of endogenous TORCs after OGD, the activity of Gal4-fusion full-length CREB (TORC activatable) and bZIP-less CREB (TORC silent) was monitored. The activity of the full-length CREB, but not bZIP-less CREB, was enhanced after OGD ( Figure 1D ), suggesting that TORCs may contribute to the Ser 133-independent activation of CREB after OGD reoxygenation.
Dephosphorylation of TORC1 Occurs after Reoxygenation A high level of TORC1 protein and a moderate level of TORC2 protein were detected in primary cortical cultures ( Figure S2A ). Under basal conditions, endogenous TORC1 was predominantly localized in the cytoplasm of cortical neurons (Figure 2A, control) . Although the phosphorylation levels of CREB at Ser133 were increased during OGD ( Figure S1A ), TORC1 remained in the cytoplasm before reoxygenation but quickly translocated into the nucleus after reoxygenation (Figure 2A ). Indeed, GFP-TORC1 translocated into the nucleus in response to OGD ( Figure S2B ). Next, we examined the intracellular distribution of TORC1 in response to OGD by separately isolating nuclei from cytoplasmic compartments. OGD followed by reoxygenation induced the nuclear localization of TORC1 ( Figure S2C ). This process was accompanied by the dephosphorylation of TORC1 at Ser 167 (corresponding Ser residues: Ser171 [TORC2] and Ser163 [TORC3]) ( Figure 2B ), followed by the enhancement of its coactivator activity ( Figure 2C ). This reoxygenation-induced activation of TORC1 may be essential for CREB activation because the overexpression of a dominantnegative TORC1 (DN-TORC1, N-terminal 56 amino acids) strongly inhibited CRE activity after OGD ( Figure 2D ) and aggravated cell injury after OGD ( Figure 2E ).
To elucidate the role of TORC1 in neuronal survival, we determined the relationship between CRE activity and cell death. We found that CRE activity in cortical neurons was enhanced by the overexpression of TORC1, and a constitutively active TORC1 (S167A) further upregulated CRE activity ( Figure 2F ). The overexpression of TORC1 or the TORC1S167A mutant resulted in a significant decrease of ischemic neuronal death ( Figure 2G ). The overexpression of TORC1 in cortical neurons induced the mRNA expression of CREB-dependent pro-survival genes, such as Ppargc-1a (PGC-1a) and BDNF ( Figure 2H ). In contrast, DN-TORC1 inhibited the upregulation of these genes after OGD ( Figure S2D ). Moreover, the OGD-induced reporter activity of Ppargc-1a and bdnf promoters was impaired by mutating their CREs ( Figure S2E ), suggesting that TORC1-CREB may actively determine neuronal survival after ischemia.
Suppression of SIK2 Enhances Neuronal Survival after OGD TORC family coactivators are phosphorylated by SIK1, SIK2, and AMPK (Katoh et al., 2006; Koo et al., 2005; Screaton et al., 2004; Takemori and Okamoto, 2008) , and quantitative PCR analyses suggest a high level of SIK1 and SIK2 mRNA in the cortex ( Figure S3A ). We found that SIK2 protein was expressed in the hippocampus and cortex (Figures S3B and S3C) and was abundant in nonstimulated neurons ( Figure S3D) ; however, SIK1 protein was not detected in these cells (data not shown) with a highly purified anti-SIK1 antibody (Uebi et al., 2010) . Next, we examined the involvement of these kinases in the regulation of TORC1 after OGD in cortical neurons ( Figure 3A) . The level of SIK1 remained low during and after OGD. The level of pAMPK increased during OGD but quickly returned to the basal level after reoxygenation. In contrast the level of SIK2 decreased in an early phase of reoxygenation ($3 hr), and it was maintained at a low level until 24 hr post-reoxygenation, suggesting that this downregulation of SIK2 may be important for the activation of TORC1-CREB after reoxygenation. Therefore, we next determined the contribution of SIK2 to the regulation of TORC1 in cortical neurons.
To elucidate the importance of SIK2, we tried to identify small compounds that could inhibit SIK2 activity more selectively than staurosporine. Fortunately, by the use of a small kinase-inhibitor library, we identified Compound C, a potent inhibitor of AMPK, as a SIK2 inhibitor ( Figure S3E ). The effective dose of Compound C against SIK2 in cultured cells was 10-fold lower than that against SIK1 or AMPK ( Figures S3F and S3G ). The IC 50 of Compound C for the SIK2-dependent suppression of forskolininduced CRE activity was approximately 0.3 mM, whereas the concentration required to inhibit the AMPK-mediated phosphorylation of acetyl-CoA carboxylase (ACC) was greater than 3 mM ( Figure S3G ). The dose response of Compound C suggested that 0.1-1.0 mM would enable us to distinguish its effect on SIK2 from its effects on SIK1 or AMPK. Indeed, 0.3-0.5 mM of Compound C upregulated CRE activity in cultured neurons after OGD ( Figure S3H ) and reduced neuronal death ( Figure S3I the other hand, we demonstrated that Compound C, at the dose used for AMPK inhibition (>3 mM), was toxic to cortical neurons after OGD ( Figure S3I ). These findings suggested that SIK2 could have a greater effect on TORC1-CREB activity than SIK1 or AMPK.
The overexpression of SIK2 and its constitutively active form (S587A) strongly inhibited CRE activity after OGD ( Figure 3B ), whereas the kinase-defective SIK2 (K49M) failed to suppress CRE activity. In agreement with the CRE-reporter assay, the overexpression of S587A increased cell death, whereas K49M decreased cell death after OGD ( Figure 3C ). Furthermore, the overexpression of the S587A mutant SIK2 resulted in a substantial amount of TORC1 in the cytoplasm after OGD ( Figure 3D ). The overexpression of SIK2 also suppressed the TORC1-dependent activation of CRE, and SIK-resistant TORC1 (S167A) blocked this suppression ( Figure 3E ).
When SIK2 was knocked down using SIK2-specific microRNA (miRNA) ( Figure 3F ), CRE activity was relatively enhanced in the late phase after OGD (after 12 hr; Figure 3G ). The knockdown of SIK2 also attenuated neuronal death after OGD ( Figure 3H ). Although overexpression of TORC1 did not confer an additional protective effect under SIK2 downregulation, the overexpression of DN-TORC1 abolished the protective effect of SIK2-specific miRNA ( Figure 3H ). These findings suggested that SIK2 plays an essential role in neuronal survival after OGD via a TORC1-dependent pathway.
CaMK I/IV Is an Upstream Regulator of TORC1 Signaling in Neurons
To determine which kinase cascades mediate the activation of CRE-dependent transcription, we pretreated cortical neurons with various kinase inhibitors and found that KN93, a CaMK II/IV inhibitor, blocked CRE-mediated transcription after OGD ( Figure 4A ). Gal4-fusion TORC1 activity was also inhibited by KN93 ( Figure 4B ), and KN-93 also blocked the decrease in the levels of SIK2 protein after OGD ( Figure S4A) . (E) The LDH assay was performed using adeno-EGFP-or adeno-DN-TORC1-transfected primary cortical neurons subjected to OGD for 2 hr and reoxygenation for 24 hr ( + p < 0.05 compared with EGFP groups; n = 10). (F) Transient assay showing the effect of wild-type or S167A mutant TORC1 on CRE-luc reporter activity in cortical neurons exposed to OGD. Data are representative of at least four independent experiments. (G) The LDH assay was performed using adeno-EGFP, adeno-TORC1, or adeno-TORC1 S167A-transfected primary cortical neurons subjected to OGD for 3 hr and reoxygenation for 24 hr ( #,+ p < 0.05 compared with EGFP groups; n = 14).
(H) Real-time RT-PCR analysis of PGC-1a and BDNF mRNA expression as a ratio of b-actin mRNA expression in adeno-EGFP or adeno-TORC1-transfected primary cortical neurons. A significant upregulation in Ppargc-1a and BDNF mRNA expression was observed for adeno-TORC1-transfected primary cortical neurons. Error bars represent ± SD; #,+ p < 0.05; ##,++ p < 0.01.
Neuron
Role of SIK2-TORC1 in Neurotoxicity
To identify the specific isoform of CaMK that is implicated in TORC-CREB-dependent transcription, dominant-active forms of CaMKs (DA-CaMK I; dominant-active CaMK I [catalytic domain], DA-CaMK IIA [catalytic domain], and DA-CaMK IV [full-length protein without its auto-inhibitory domain]) were expressed in Gal4-fusion reporter systems ( Figure 4C ). The activity of TORC-responsive CREB and TORC-non-responsive CREB (Gal4-CREB bZIP-less) were upregulated by the overexpression of CaMK I and IV, but not by CaMK IIA. In addition to CREB, CaMK I and IV upregulate TORC1 activity ( Figure 4C ). Conversely, DN (dominant negative; kinase-dead form)-CaMK I (K49E) and DN-CaMK IV (K75E) blocked TORC1-mediated transcriptional activity after OGD ( Figure 4D ) and SIK2 degradation after OGD ( Figure S4B) . Also, the overexpression of (E) Transient assay of cortical neurons cotransfected with wild-type SIK2, and either wild-type-or S167A-TORC1-expressing viruses. A fixed amount of either wild-type-or S167A-TORC1-expressing viruses and escalating amounts of SIK2-expressing viruses were used. Luciferase activity from adeno-CRE reporters is shown.
(F) Knockdown of SIK2 with SIK2-specific miRNA in primary cortical neurons.
(G) Knockdown of SIK2 with miRNA leads to enhanced CRE activity after OGD. Primary cortical neurons were cotransfected with LacZ-or SIK2-specific miRNAiexpressing adenoviruses and CRE reporters. At 4 days postinfection, cells were harvested for the luciferase assay after OGD. (H) LDH assay after transfection with LacZ-or SIK2-specific miRNAi-expressing adenoviruses after OGD (n = 12). Additionally, the LDH assay was performed under conditions of SIK2 knockdown by using SIK2 miRNA in combination with the overexpression of adeno-EGFP, adeno-TORC1, or adeno-DN-TORC1. Error bars represent ± SD; #,+ p < 0.05.
DN-TORC1 resulted in a significant reduction in CRE activity that was enhanced by CaMK I or CaMK IV in cortical neurons under control conditions and after OGD ( Figure S4C ). This finding suggested that CaMK I and IV may be able to activate CREB (via phosphorylation at Ser133) and TORC. Endogenous CaMK IV is predominantly restricted to the nucleus, whereas overexpressed CaMK IV was localized in both the cytoplasm and nucleus ( Figure S4D ). To determine the role of endogenous CaMK IV, we confirmed its involvement in the regulation of OGD-induced TORC activation by means of RNA interference (RNAi) experiments. Treatment with rat CaMK IV-specific miRNA decreased the level of CaMK IV, not CaMKI ( Figure S4E ). We found that the knockdown of CaMK IV resulted in the inhibition of TORC1 activity ( Figure S4F ) and aggravated cell injury after OGD ( Figure S4G ). Furthermore, transfection of human CaMK IV, which is resistant to miRNA for rat CaMK IV, reversed the CaMK IV protein level and attenu- Cortical neurons were transfected with the Ad-CRE-fluc reporter and Ad-TK-rluc (an internal standard). At 48 hr later, cells were treated with KT5720, KN93, U0126, LY294002, or DMSO for 6 hr, and then subjected to OGD and reoxygenation.
(B) CaMK is responsible for TORC1 activity in cortical neurons. Primary cortical neurons were cotransfected with adeno-GAL4-fusion TORC1 and the Adeno-5 3 GAL4-luciferase reporter with the internal reporter Adeno-TK-rluc. The specific transfection activity of TORC1 was expressed as the fold activation of the empty adeno-GAL4 vector pM.
(C) Primary cortical neurons were cotransfected with either the EGFP-, DA-CaMK I-, DA-CaMK IIA-, or DA-CaMK IV-expressing adenoviruses, and Adeno-GAL4-CREB (full length) (left), Adeno-GAL4-CREB bZIP-less (middle), or Adeno-GAL4-TORC1 (right) and the Adeno-5 3 GAL4-luciferase reporter with Adeno-TK-rluc.
(D) TORC1 activity in cortical neurons transfected with DN-CaMK I-(K49E), DN-CaMK IV-(K75E), or EGFP-expressing adenoviruses at the early (3 hr) or delayed phase (12 hr) after OGD.
(E) Primary cortical neurons were transfected with DA-CaMK IV-expressing adenoviruses relative to LacZ-expressing adenoviruses, and an LDH assay was performed after OGD. Error bars represent ± SD; + p < 0.05; ++ p < 0.01. ated the cell injury by CaMK IV knockdown ( Figures S4E and S4G ). These results suggested that CaMK IV may upregulate CRE-mediated transcription in a CREB Ser133-and TORC1-dependent manner. Indeed, the overexpression of DA-CaMK IV significantly decreased neuronal injury after OGD ( Figure 4E ). On the basis of these findings, CaMK I and CaMK IV were identified as negative regulators of SIK2. nifedipine, or the NR2B-containing NMDAR-specific inhibitor Ro25-6981 did not show any effect on TORC1-mediated transcriptional activity ( Figure 5A ). Treatment with NVP-AAM0077 inhibited the nuclear localization of TORC1 ( Figure 5B ) and SIK2 degradation after OGD ( Figure 5C ). Although the subunit specificity of NVP-AAM0077 is debated (Neyton and Paoletti, 2006) , these findings suggested that the activation of NR2A-containing NMDARs results in the degradation of SIK2 following CaMK I/IV activation, leading to enhanced TORC1 activity after OGD. Next, to determine whether stimulation of NR2A-containing NMDARs leads to the activation of the SIK2-TORC1-CREB cascade, we treated neurons with bicuculline (Bic) and 4-aminopyridine (4-AP), which have been shown to stimulate neuronal synapses and activate NR2A receptors (Hardingham et al., When cortical neurons were treated with the Bic and 4-AP, SIK2 protein levels were decreased ( Figure 5D ), and subsequently led to the nuclear localization of TORC1 ( Figure 5E ) and the increase of TORC1-mediated transcriptional activity ( Figure 5F ). On the other hand, when neurons were treated with the NR2A-specific antagonist, NVP-AAM0077, together with Bic and 4-AP, SIK2 degradation was blocked ( Figure S5A ) and was followed by a decrease in the activation of TORC1-mediated transcriptional activity ( Figure S5B ). DN-CaMK I (K49E) and IV (K75E) blocked the TORC1-mediated transcriptional activity induced by Bic and 4-AP ( Figure S5C ). Furthermore, DN-TORC1 inhibited CRE activity after the treatment with Bic and 4-AP ( Figure S5D ).
Destabilization of SIK2 by CaMK I/IV-Mediated Phosphorylation at Thr 484
We then examined whether the Ca 2+ /CaMK I/IV pathway could reduce the level of SIK2 protein after OGD (shown in Figure 3A ). A decrease in the level of protein is often the result of protein degradation via the proteasome, and the proteasomal inhibitor lactacystin has been shown to stabilize SIK1 and SIK2 (Katoh et al., 2006; Takemori and Okamoto, 2008) . Thus, we treated the cells with lactacystin and found that the inhibitor blocked the decrease of SIK2 protein levels in cells subjected to OGD ( Figure 6A ). cAMP-PKA phosphorylates SIK2 at Ser587 and downregulates TORC-phosphorylation activity of SIK2, but it does not change its protein level (Katoh et al., 2006; Takemori and Okamoto, 2008) . On the other hand, the overexpression of CaMK I/IV decreased SIK2 protein levels (bottom panel in Figure 6B ). Also, a Ser587 residue in the C-terminal regulatory domain of SIK2 is autophosphorylated and negatively regulates its TORC-phosphorylation activity (Katoh et al., 2006; Takemori and Okamoto, 2008) . Because the S587A mutant negatively regulates CRE activity ( Figure 3B ), we examined the involvement of Ser587 phosphorylation in SIK2 degradation. However, the level of Ser587 phosphorylation was almost similar in cells (E) The phosphorylation of SIK2 Thr484, not Ser587, occurs prior to the degradation of SIK2 in cortical neurons after OGD. Primary cortical neurons were harvested after the indicated periods following OGD. Cells were subjected to immunoprecipitation (IP) using anti-SIK2 sera followed by western blotting using Ser587-or Thr484-specific antibodies.
(F) Neurons were cotransfected with LacZ-or T484A-SIK2-expressing adenoviruses, and the cells were exposed to OGD-reoxygenation after 48 hr. The immunofluorescent localization of endogenous TORC1 was examined. Scale bar, 25 mm.
(G) Cortical neurons were cotransfected with T484A SIK2-or EGFP-expressing adenoviruses, and Ad-CRE-fLuc and Ad-TK-rLuc. CRE activity was measured at the early (3 hr) or late phase (12 hr) after OGD. (H) Neurons were transfected with wild-type-or T484A-SIK2, and SIK2 protein levels were monitored by using immunoblotting after OGD. b-Actin was used as a loading control. Error bars represent ± SD; + p < 0.05.
overexpressing DA-CaMK I and IV compared to GFP-expressing cells (middle panel in Figure 6B ). Therefore, we decided to identify the other CaMK phosphorylation sites in SIK2 that contained the CaMK motif R/K-X-X-S/T (White et al., 1998) by lining up the domains that are conserved from insects to vertebrates. We found that Thr484 is a candidate site for CaMK-mediated phosphorylation ( Figure 6C ). Indeed, a specific antibody against phospho-Thr484 revealed enhanced Thr484 phosphorylation in neurons overexpressing DA-CaMK I and IV (upper panel in Figure 6B ). To further examine whether CaMK could directly phosphorylate SIK2 at Thr484, we performed an in vitro kinase assay. The in vitro kinase assay using a GST-fusion Thr484-peptide (GQRRHT 484 LSEVT) provided evidence that Thr484 is a good substrate for CaMK I and IV ( Figure 6D ). Time course experiments clearly showed that the level of phosphorylation at Thr484, but not at Ser587, was elevated after OGD ( Figure 6E ). The overexpression of CaMK I or IV partially inhibited the suppression of CRE activity induced by wild-type SIK2 but had no effect on the CaMK-resistant SIK2 mutant T484A ( Figure S6 ). The SIK2 T484A mutant blocked the nuclear entry of TORC1 ( Figure 6F ) and CRE activity ( Figure 6G ) in cortical neurons subjected to OGD. Moreover, the decrease in SIK2 protein levels after OGD-reoxygenation was inhibited in neurons overexpressing the SIK2 T484A mutant compared to neurons overexpressing wild-type SIK2 ( Figure 6H ). On the basis of these findings, we suggest that the phosphorylation of SIK2 at Thr484 occurs prior to and may be necessary for the degradation of SIK2 in cortical neurons.
Enhanced Neuronal Survival after OGD in sik2 Knockout Mice
The data from primary cortical neurons indicated that SIK2 plays a key role in mediating neuronal protection by regulating gene expression through CREB-TORC1 signaling. To further elucidate the role of SIK2 in vivo, we generated mice with a deletion of the sik2 gene ( Figures S7A and S7B ). These Sik2 À/À mice apparently had no phenotype for body weight control, whereas the mice facilitated eumelanin (black melanin) synthesis in their hair follicle melanocytes . When we prepared primary cortical cultures from wild-type and sik2 À/À mice, and subjected them to reporter assays, we found enhanced CRE activity (Figure 7A ) and TORC1 coactivator activity ( Figure 7B ) in neurons derived from sik2 À/À mice after OGD compared with wild-type mice. After OGD the number of surviving neurons isolated from sik2 À/À mice was much higher than from wild-type mice (Figure 7C ). To confirm that such protection from ischemic brain injury was due to sik2 deficiency, re-expression experiments were performed by transfecting SIK2 À/À neurons with SIK2 (Figure S7C) . Transfection of SIK2 in SIK2 À/À neurons decreased CRE activity and increased ischemic neuronal injury compared with neurons that were transfected with EGFP. In addition, high levels of promoter activity for Ppargc-1a, BDNF, and Trk-B were observed in sik2 À/À neurons after OGD ( Figure 7D ).
These results suggested that SIK2 knockdown promotes the neuroprotective program by upregulating TORC-CREB activity followed by the increased expression of neuroprotective CREB target genes.
SIK2 Knockout Mice Are More Resistant to Focal Cerebral Ischemia
To investigate the role of SIK2 on neuroprotection in vivo, mice were subjected to 60-min middle cerebral artery occlusion (MCAO) followed by 48 hr reperfusion. We assessed the intracellular distribution of TORC1 and SIK2 proteins after MCAO (Figure S8) . Similar to the in vitro experiments, ischemia triggered the nuclear translocation of TORC1 ( Figures S8A and S8B ) and the degradation of SIK2 in the ischemic cortex after MCAO ( Figure S8C ). In contrast, SIK1 levels remained low after MCAO ( Figure S8C ). In line with the findings of in vitro OGD, we observed that the level of Thr484 phosphorylation of SIK2 increased after MCAO ( Figure S8D ). Next, to investigate the effect of SIK2 deficiency on neuroprotection, wild-type and sik2 À/À mice were subjected to 60-min MCAO followed by 48-hr reperfusion. We found no differences in their basal physiological parameters, including rectal temperature, brain skull temperature, and mean arterial blood pressure. Residual cerebral blood flow in the ischemic hemisphere was comparable in sik2 À/À and wild-type mice at all time points during and after ischemia (data not shown). In wild-type mice, we observed no significant difference in the phosphorylation levels of TORC1 at Ser167 between the ipsilateral and contralateral regions at 24 hr after MCAO ( Figure 8A) ; however, in SIK2 null mice there was a 50% reduction in the phosphorylation level of TORC1 (Figure 8A ). There were no significant differences in the expression of SIK1 and SIK3 between wild-type and SIK2 null mice, suggesting no compensatory upregulation of SIK1 or SIK3 expression in SIK2 null mice ( Figure S7D ). Importantly, ischemic lesions after MCA occlusion were markedly smaller in SIK2 null mice (27.2 ± 5.8 mm 3 ) than in wild-type mice (69.1 ± 6.1 mm 3 ) ( Figures 8B  and 8C ).
We suspected that several key genes contributed to the neuronal protection observed following SIK2 deletion. To address this point, quantitative RT-PCR of cerebral cortex subjected to MCAO or sham operation was used to examine the levels of previously identified CREB target genes and other CREB-independent genes in SIK2 null mice. The mRNA levels for Ppargc-1a and BDNF were higher in sik2 À/À mice than in wild-type mice, whereas the mRNA levels of Trk-B in sik2 À/À mice were not significantly different compared to wild-type mice ( Figure 8D ). The mRNA levels of CREB-independent genes such as HSP70 and TGF-b were almost similar in sik2 À/À and wild-type mice. However, the mRNA levels of the proinflammatory cytokine TNF-a were significantly suppressed in sik2 À/À mice compared to wild-type mice after MCAO.
DISCUSSION
We presented evidence that SIK2 and the transcriptional coactivator TORC1-CREB are important for neuronal survival after ischemic injury ( Figure 8E ). We previously demonstrated that, after exposure of cultured hippocampal neurons to glutamate, the inhibition of CREB activity by a CRE-decoy oligonucleotide or by the CaMK inhibitor KN93 resulted in a reduction in the expression of the anti-apoptotic factor Bcl-2 (Mabuchi et al., 2001) . Thus, we hypothesized that CREB plays a pivotal role in neuroprotection following ischemia-reperfusion. In fact, other groups have also demonstrated the involvement of CREB dysregulation in a broad range of neurological diseases (Mantamadiotis et al., 2002; St-Pierre et al., 2006; Okamoto et al., 2009 ). In particular the activation of the CREB-PGC-1a cascade may contribute to neuronal cell survival in various neurological diseases, including stroke, Huntington disease, and Parkinson disease (Okamoto et al., 2009; St-Pierre et al., 2006) . Although other studies have implicated CREB, where phosphorylation at Ser133 in its kinase-inducible domain is often equated with transcription of CREB target genes, Ser133 alone is not sufficient to activate target genes containing CRE (Kitagawa, 2007; Lonze and Ginty, 2002; Mabuchi et al., 2001) . In fact the selective recruitment of CBP/p300 and perhaps other coactivators may determine gene activation via the CREB bZIP were cotransfected with adeno-GAL4-fusion TORC1 and the Adeno-5 3 GAL4-luciferase reporter with the internal reporter Adeno-TK-rluc. At 48 hr postinfection, cells were harvested for the luciferase assay after the indicated periods following OGD. (C) SIK2 deficiency renders neurons more resistant to OGD. Primary cortical cultures generated from wild-type or sik2 À/À mice were exposed to OGD, and the loss of MAP2 integrity (left) and the level of neuronal injury at 24 hr were determined using an LDH assay (right). Scale bar, 100 mm.
(D) Enhanced expression of CRE target genes in cortical neurons from sik2 À/À mice. Cortical neurons were cultured from wild-type or sik2
mice. Neurons were transiently transfected with the PGC-1a promoter 2 kb luciferase-adenovirus (left panel), À400/+2 BDNF exon IV-luciferaseadenovirus (center panel), or À1429/+2 Trk-B (right panel), and ad-TK-rluc. At 48 hr postinfection, neurons were exposed to OGD, and a luciferase assay was performed at 24 hr after OGD. Error bars represent ± SD; + p < 0.05; ++ p < 0.01.
domain (Schumacher et al., 2000) . Although a number of CREB target genes for neuroprotection have been identified, some discrepancies have also been found in the transcriptional regulation of these genes. The first discrepancy is a difference in the temporal profiles between the levels of CREB Ser133 phosphorylation and CRE activity and the subsequent induction of putative CREB target genes. In developing cortical neurons, it has been recently reported that CREB DNA binding is tightly controlled by extracellular stimuli such as neurotrophins, and an NO-signaling pathway controls CREB binding independent of CREB Ser133 phosphorylation (Riccio et al., 2006) . These findings suggest the existence of essential factors other than phospho-Ser133 or its interacting molecules, i.e., CBP/p300, that may share the same activation mechanism as phosphoSer133. We show here that, in cortical neurons, the dephosphorylation of TORC1 and the subsequent nuclear import of TORC1 by Ca 2+ led to the activation of CREB and its downstream target genes.
Similar mechanisms have been studied in the gluconeogenic program in the liver. For example, glucagon-cAMP signaling promotes CREB-dependent gluconeogenic gene expression, whereas insulin inhibits this promotion. Paradoxically, insulin signaling can also phosphorylate CREB at Ser133. The paradox between the level of phospho-Ser133 and CREB activity in the gluconeogenic program can be explained by the coactivator TORC2 (Dentin et al., 2007; Koo et al., 2005) . When cAMP cascades are initiated, PKA inactivates SIKs and activates a TORC phosphatase, likely calcineurin, inducing the nuclear import of TORC2 followed by its binding to CREB (Screaton et al., 2004) . The activation of TORC2 occurs concomitantly with the phosphorylation of CREB at Ser133 because these two factors are regulated by a common upstream molecule PKA.
NMDARs constitute a major class of ionotropic glutamate receptors and play a key role in CNS physiology and pathophysiology. Functional NMDARs are heteromultimers formed by the assembly of the obligate NR1 plus either NR2A or NR2B or a mixture of the two. In particular, synaptic NR2A-and extrasynaptic NR2B-containing NMDARs have opposite effects on CREB function, gene regulation, and neuron survival (Hardingham et al., 2002; Liu et al., 2007) . In this study we showed that Ca 2+ signals, via NR2A-containing NMDARs or synaptic activity, e.g. Bic and 4-AP, activate TORC-mediated transcription mediated by the CaMK I/IV-SIK2 cascade. SIK2 was degraded via the proteasome following phosphorylation at Thr 484 by CaMK I/IV, but not CaMK II, leading to CREB-dependent neuroprotective gene expression. In addition, CaMK IV can also phosphorylate CBP and thereby stimulate CREB-dependent transcription (Hardingham et al., 1999; Impey et al., 2002) . Collectively, these findings indicate that CaMK IV may govern distinct neuronal survival pathways with Ca
2+
-dependent crosstalk between them, and converge on CREB-CRE signaling and their downstream targets. Similarly, PKA inactivates the TORCkinase activity of SIK2 by phosphorylating it at Ser587. Although Thr484 and Ser587 are located in a region that is highly conserved from insects to humans, the mechanism by which phospho-Ser587 inactivates SIK2 may be different from that of enhances the activity of CaMKs via the NR2A-containing NMDAR. Activated CaMK I/IV phosphorylates SIK2 at Thr484 followed by SIK2 degradation. The ischemia-induced degradation of SIK2 dephosphorylates TORC1 at Ser167, leading to its translocation into the nucleus. Then, TORC1 induces CREB target genes, such as Ppargc-1a and Bdnf, and leads to neuronal protection after ischemia.
phospho-Thr484 because Ser587 phosphorylation does not induce SIK2 degradation (Katoh et al., 2006) . This evidence suggests the possibility that Ca 2+ activates TORC1 via the phosphorylation of SIK2 at Thr484, whereas cAMP activates TORC1 via the phosphorylation of SIK2 at Ser587. Both pathways are accompanied by the phosphorylation of CREB at Ser133. This is the reason why phospho-CREB Ser 133 is recognized as representative of the induction of CREB-dependent gene expression. Consistent with previous reports, mammalian neurons in the CNS predominantly express TORC1 (Zhou et al., 2006) , and low levels of TORC2 protein are also detected in neurons (Lerner et al., 2009) . A recent study using Drosophila showed that the loss of TORC1 resulted in the enhancement of lethality with starvation and oxidative stress induced by paraquat (Wang et al., 2008) . In contrast, Drosophila expressing RNAi for SIK2 acquires resistance to the above stresses (Wang et al., 2008) . Moreover, Caenorhabditis elegans with a Kin-29 loss-of-function mutation, the ortholog of SIK, has increased longevity with a smaller body size (van der Linden et al., 2007) . In order to gain further insight into the role of SIK2, we generated sik2 À/À mice. These mutant mice are fully viable, have intact brain anatomy, and appear to develop normally. Under conditions of SIK2 knockdown using micro-SIK2 RNAi, the additive neuroprotective effects of concomitant TORC1 overexpression were no longer observed ( Figure 3H ). On the other hand, DN-TORC1 blunted SIK2 downregulation-induced neuronal protection ( Figure 3H ). Importantly, we observed enhanced neuroprotection after in vivo ischemia in sik2 À/À mice and upregulation of CREB-dependent gene expression in sik2 À/À mice. These findings suggested that SIK2 knockdown contributed to neuronal protection primarily through TORC1-CREB-dependent neuronal survival, but the change in expression of CREB-independent factors such as inflammatory cytokine TNF-a might be involved in the neuroprotection observed in sik2 À/À mice, suggesting a broad range of SIK2 function in neuronal protection. In summary we identified that SIK2-TORC1 in the CREBsignaling pathway regulates the survival of cortical neurons after brain ischemia. The results presented in the present study suggest that the SIK2-TORC1-CREB signaling pathway may serve as a potential therapeutic target for promoting the survival of neurons. These findings also raise new opportunities for the development of novel therapeutics.
EXPERIMENTAL PROCEDURES
A detailed description of all procedures is included in the Supplemental Experimental Procedures.
Antibodies
The following primary antibodies were used for immunofluorescence, immunoprecipitation, and immunoblots analysis: mouse monoclonal anti-MAP2 (Sigma), rabbit polyclonal anti-phospho-CREB (pCREB) (Upstate Biotechnology), rabbit polyclonal anti-CREB (Upstate, Bio) rabbit anti-phospho-AMPK (pAMPK) (NEB), and rabbit anti-AMPK (NEB).
TORC1 antisera were raised against human TORC1 (551-650) and TORC3 (480-619) peptides. As these antisera cross-reacted with TORC1 and TORC3, the IgG was purified from the anti-TORC1 serum using the TORC3 peptide. The resultant anti-TORC1/3 IgG could recognize TORC1 and TORC3 with equal efficiency. The phospho-TORC1 (Ser167), phospho-SIK2 (Thr484), phospho-SIK2 (Ser578), and anti-SIK1 antibodies were produced in our laboratory.
Primary Cortical Cultures
Primary cultures of rat cortical neurons were obtained as described previously (Mabuchi et al., 2001) . In brief, neuronal cultures were prepared from the cortex of embryonic day 16 (E16) rat embryos. Cells were used after 10-11 days in vitro when most cells showed a neuronal phenotype. See Supplemental Experimental Procedures for details. Construction of miRNA against SIK2 and CaMK IV and the Preparation of Recombinant Adenoviruses miRNA (miRNAi) oligonucleotides and complementary strands were designed to target the consensus sequence of rat SIK2 and CaMK IV. To obtain the knockdown of SIK2 and CaMK IV in cortical neurons, we constructed miRNA cassettes in an expression plasmid. A BsaI linker (5 0 -TGCTGGAGACCT TATGGTCTCA/5 0 -CCTGTGAGACCATAAGGTCTCC; the underlined sections show the recognition sites) was ligated into the cloning site of the pcDNA6.2-GW/miR vector (Invitrogen). The region containing a GFP tag and the BsaI-cloning site was transferred to the pDONR221 vector by means of BP-Clonase, and the resultant vector was named pDONR-GW/miR. Oligonucleotides for miRNA against rat SIK2 mRNA (see Supplemental Experimental Procedures) were annealed and ligated to the BsaI site of pDONR-GW/miR. In contrast, oligonucleotides for miRNA against rat CaMK IV miRNA-1, -2, -3, and -4 (see Supplemental Experimental Procedures) were ligated into the cloning site of the pcDNA6.2-GW/miR vector (Invitrogen). Although CaMK IV miRNA-1, -2, -3, and -4 each modestly attenuated (by 40%) CaMK IV expression (data not shown), chaining of these CaMK IV miRNA-1, -2, -3, and -4 to the same vector more effectively attenuated CaMK IV protein expression. The region containing the GFP tag and miRNA was then transferred to the Gateway-based pAd-CMV/DEST vector (Invitrogen) using the LR reaction according to the manufacturer's instructions. Primary cortical neurons were transfected with adeno-miRNAs. The efficacy of SIK2 miRNA or CaMK IV miRNA-1/2/3/4 was evaluated using western blot analysis at 4-5 days after the transduction of primary cortical neurons, which express endogenous SIK2 or CaMK4, with serial dilutions of concentrated miRNA. At 4 days postinfection, the cells were harvested for the luciferase assay and an LDH assay after OGD.
Dual-Glo Luciferase Assay
Primary cortical neurons were infected with the purified adenovirus (adeno-CRE-Luc [firefly] and adeno-TK-Luc [renilla]). The adenovirus containing a CMV promoter driving renilla luciferase was used as an internal control (Promega) as previously described (Katoh et al., 2006) .
Immunohistochemistry
Primary cortical neurons were fixed immediately with 4% PFA for 30 min. For double-immunofluorescence in vivo, free-floating sections (40 mm) were used. See Supplemental Experimental Procedures for details.
In Vitro Phosphorylation of SIK2 by CaMKs
To prepare an SIK2-Thr484 peptide, a set of oligonucleotides for the SIK2 peptide (Gly479 to Thr489: 5 0 -gatcGGGCAGCGACGGCACACTCTGTCAG AAGTGACT and 5 0 -aattAGTCACTTCTGACAGAGTGTGCCGTCGCTGCCC) was cloned into the BamHI/EcoRI site of the Escherichia coli GST-fusion vector pGEX6P-1, and the GST-SIK2 (Thr484) peptide was purified by using a glutathione-Sepharose column. To prepare active CaMKs, cDNA fragments for constitutive active CaMKs were ligated into the BamH1/NotI site of pEBG mammalian GST-fusion vector, and the active CaMKs were expressed in COS-7 cells followed by purification with a glutathione-Sepharose column. The GST-SIK2 (Thr484) peptide (1 mg) was incubated with CaMKs in a reaction buffer (10 mM Tris-HCl [pH 7.4], 10 mM MgCl 2 , in the presence or absence of 100 mM ATP) at room temperature for 1 hr, and phospho-SIK2 (Thr484) was detected by western blot analyses with anti-phospho-Thr484 antiserum.
Immunoprecipitation and Immunoblots
These were performed as previously described (Katoh et al., 2006 ) (see Supplemental Experimental Procedures). Data are representative of at least four independent experiments.
Quantitative Real-Time PCR Analysis Total RNA was extracted by using TRIzol (Invitrogen). cDNAs were prepared by reverse transcription (RT) from total RNA (1 mg) by using SuperScript III and random primers (Invitrogen). One-hundredth of the RT products and standard plasmids were subjected to real-time PCR analyses with the iQ SYBR Green Supermix (Invitrogen) or TaqMan Probe Universal PCR Master Mix (Applied Biosystems). The specific primers used are listed in Table S1 . See Supplemental Experimental Procedures for details.
Generation of Sik2 -/-Mice
The generation of Sik2 +/À mice has been described by Horike et al. (2010) 
Cell Viability Assays
Neuronal injury was measured at 24 hr after OGD for 3 hr with lactate dehydrogenase (LDH) using the Cytotoxicity Detection Kit (Roche Applied Science). When we examined the effect of DN-TORC1 transfection and CaMK IV-specific miRNA on neuronal survival, cultured neurons were exposed to OGD for 2 hr, followed by reoxygenation. In a sister culture, 100% cell death was induced using 2 mmol/l NMDA. The relative assessments of neuronal injury were normalized by comparison with 100% cell death.
Transient Focal Ischemia
The right-middle cerebral artery was occluded for 60 min using a suture and then reperfused. As described previously (Kitagawa et al., 1998) , only mice with less than 30% of the baseline control microperfusion during the first minute of occlusion were used in subsequent experiments. See Supplemental Experimental Procedures for details.
Statistical Analysis
All results are reported as the mean ± standard deviation (SD), and analyses were performed using SPSS software. Three experimental groups were compared using the Kruskal-Wallis test or one-way analysis of variance (ANOVA) with Scheffe's post hoc pairwise analyses. Two experimental groups were compared with Student's unpaired two-tailed t test. Statistical significance was defined as p < 0.05.
SUPPLEMENTAL INFORMATION
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